Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JAZZ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsJazz Pharmaceuticals CCO Samantha Pearce to retire by June 2027; search for successor underway
Filed October 9, 2026 · Period ending October 6, 2026 · ~1 min read
Key Changes
-
medium
Chief Commercial Officer Samantha Pearce notified Jazz Pharmaceuticals on October 6, 2026 of her intent to retire, effective upon the earlier of successor appointment or June 30, 2027.
Item 5.02 verify on EDGAR → -
medium
The company will begin a formal search process considering both internal and external candidates for the CCO role.
Item 5.02 verify on EDGAR →
Summary
Jazz Pharmaceuticals disclosed that its Executive Vice President and Chief Commercial Officer, Samantha Pearce, has informed the company of her intention to retire. Her departure will occur upon the earlier of the appointment of her successor or June 30, 2027, providing a transition period of up to nine months. The company stated it will initiate a formal search process that includes both internal and external candidates.
For retail investors, this is a planned leadership transition with a defined timeline and no indication of disagreement or abrupt departure. The extended transition window and structured search process suggest continuity in the commercial organization. The filing does not flag any concerns regarding the company's operations or strategy.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company”), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.
Samantha Pearce, the company's Executive Vice President and Chief Commercial Officer, has notified Jazz Pharmaceuticals of her intent to retire. Her retirement will take effect upon the earlier of the appointment of her successor or June 30, 2027. The company plans to begin a formal search process considering both internal and external candidates.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Oct 13, 2026 · How we verify